ImmuCell (ICCC) Competitors

Alpha Teknova (NASDAQ:TKNO) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Which has more volatility & risk, TKNO or ICCC?

Alpha Teknova has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Does the media favor TKNO or ICCC?

In the previous week, ImmuCell had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for ImmuCell and 0 mentions for Alpha Teknova. ImmuCell's average media sentiment score of 0.80 beat Alpha Teknova's score of 0.00 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Teknova	Neutral
ImmuCell	Positive

Do insiders and institutionals believe in TKNO or ICCC?

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by insiders. Comparatively, 5.6% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is TKNO or ICCC more profitable?

ImmuCell has a net margin of 6.23% compared to Alpha Teknova's net margin of -55.24%. ImmuCell's return on equity of 6.25% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-55.24%	-26.51%	-18.40%
ImmuCell	6.23%	6.25%	3.87%

Which has preferable earnings & valuation, TKNO or ICCC?

ImmuCell has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$37.74M	6.73	-$26.75M	-$0.42	-11.31
ImmuCell	$28.27M	1.95	-$2.16M	$0.19	32.05

Do analysts recommend TKNO or ICCC?

Alpha Teknova currently has a consensus price target of $10.00, indicating a potential upside of 110.53%. Given Alpha Teknova's stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Teknova is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
ImmuCell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Alpha Teknova beats ImmuCell on 9 of the 17 factors compared between the two stocks.